$0.29
3.89% yesterday
Nasdaq, Apr 03, 10:14 pm CET
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

FibroGen, Inc. Target price 2025 - Analyst rating & recommendation

FibroGen, Inc. Classifications & Recommendation:

Buy
50%
Hold
50%

FibroGen, Inc. Price Target

Target Price $10.00
Price $0.29
Potential
Number of Estimates 1
1 Analyst has issued a FibroGen, Inc. price target 2026. The average FibroGen, Inc. target price is $10.00. This is higher than the current stock price.
A rating was issued by 2 analysts: 1 Analysts recommend FibroGen, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the FibroGen, Inc. stock has an average upside potential 2026 of . Most analysts recommend the FibroGen, Inc. stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 29.62 6.00
36.71% 79.74%
EBITDA Margin -433.05% -1,135.00%
32.49% 162.09%
Net Margin -163.54% -1,000.79%
74.03% 511.94%

2 Analysts have issued a sales forecast FibroGen, Inc. 2025 . The average FibroGen, Inc. sales estimate is

$6.0m
Unlock
. This is
96.15% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$6.0m 96.15%
Unlock
, the lowest is
$6.0m 96.15%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $29.6m 36.71%
2025
$6.0m 79.74%
Unlock
2026
$7.0m 16.67%
Unlock
2027
$121m 1,633.57%
Unlock
2028
$270m 122.83%
Unlock

1 Analyst has issued an EBITDA forecast FibroGen, Inc. 2025 . The average FibroGen, Inc. EBITDA estimate is

$-68.1m
Unlock
. This is
55.66% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-68.1m 55.66%
Unlock
, the lowest is
$-68.1m 55.66%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-128m 57.27%
2025
$-68.1m 46.91%
Unlock
2026
$-69.1m 1.47%
Unlock
2027
$-64.4m 6.80%
Unlock
2028
$-62.7m 2.64%
Unlock

EBITDA Margin

2024 -433.05% 32.49%
2025
-1,135.00% 162.09%
Unlock
2026
-987.14% 13.03%
Unlock
2027
-53.07% 94.62%
Unlock
2028
-23.19% 56.30%
Unlock

2 FibroGen, Inc. Analysts have issued a net profit forecast 2025. The average FibroGen, Inc. net profit estimate is

$-60.1m
Unlock
. This is
23.96% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-31.3m 35.41%
Unlock
, the lowest is
$-88.8m 83.33%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-48.4m 83.56%
2025
$-60.1m 23.96%
Unlock
2026
$-78.2m 30.24%
Unlock
2027
$-58.5m 25.16%
Unlock
2028
$-44.4m 24.14%
Unlock

Net Margin

2024 -163.54% 74.03%
2025
-1,000.79% 511.94%
Unlock
2026
-1,117.33% 11.64%
Unlock
2027
-48.24% 95.68%
Unlock
2028
-16.42% 65.96%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.48 -0.60
83.56% 25.00%
P/E negative
EV/Sales 18.57

2 Analysts have issued a FibroGen, Inc. forecast for earnings per share. The average FibroGen, Inc. EPS is

$-0.60
Unlock
. This is
25.00% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.31 35.42%
Unlock
, the lowest is
$-0.88 83.33%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.48 83.56%
2025
$-0.60 25.00%
Unlock
2026
$-0.78 30.00%
Unlock
2027
$-0.58 25.64%
Unlock
2028
$-0.44 24.14%
Unlock

P/E ratio

Current -0.61 23.75%
2025
-0.49 19.67%
Unlock
2026
-0.38 22.45%
Unlock
2027
-0.51 34.21%
Unlock
2028
-0.67 31.37%
Unlock

Based on analysts' sales estimates for 2025, the FibroGen, Inc. stock is valued at an EV/Sales of

18.57
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.71 49.65%
2025
18.57 2,515.03%
Unlock
2026
15.91 14.29%
Unlock
2027
0.92 94.23%
Unlock
2028
0.41 55.12%
Unlock

P/S ratio

Current 0.19 87.88%
2025
4.95 2,499.79%
Unlock
2026
4.24 14.28%
Unlock
2027
0.24 94.23%
Unlock
2028
0.11 55.13%
Unlock

Current FibroGen, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 18 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 20 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 18 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 20 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today